Follow Us
© 2026 Arizent. All rights reserved.
Brain signals in patients taking weight-loss drugs such as Novo Nordisk’s Ozempic may contribute to lowering heart disease and deaths, researchers said.
Ozempic, Novo’s Wegovy and Eli Lilly‘s Zepbound work in part by mimicking GLP-1, a hormone that moderates appetite and fights obesity, a known risk factor for heart disease. The drugs also activate anti-inflammatory pathways in the brain with far-reaching effects that may independently keep the heart healthy, according to a study.
For reprint and licensing requests for this article, click here.
A look at what the Medicare GLP-1 Bridge Program covers, what it doesn't, and what plan sponsors need to know.
Only 4.4% of newly-eligible patients would be covered by the projected $900 million in savings, according to new research.
Novo Nordisk will cut prices for Ozempic and Wegovy by up to 50% next year, prompting employers to plan for rising use and manage benefits costs.
You Powered Symposium earmarks $50,000 between Radial's treatment for a wide range of brain disorders and Hibiscus Health's cardiometabolic risk screening.
Direct-to-employer carve-outs can make drugs like GLP-1s more affordable for companies and more accessible for employees.
